These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 22174000)
41. Multiparametric magnetic resonance imaging of the prostate. Neto JA; Parente DB Magn Reson Imaging Clin N Am; 2013 May; 21(2):409-26. PubMed ID: 23642560 [TBL] [Abstract][Full Text] [Related]
42. Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project. Muller BG; van den Bos W; Brausi M; Cornud F; Gontero P; Kirkham A; Pinto PA; Polascik TJ; Rastinehad AR; de Reijke TM; de la Rosette JJ; Ukimura O; Villers A; Walz J; Wijkstra H; Marberger M BJU Int; 2014 Nov; 114(5):698-707. PubMed ID: 24180365 [TBL] [Abstract][Full Text] [Related]
43. MR assessment of recurrent prostate cancer after radiation therapy. Rouvière O Radiology; 2007 Feb; 242(2):635-6; author reply 636-7. PubMed ID: 17255435 [No Abstract] [Full Text] [Related]
44. Prostate cancer localization using multiparametric MRI based on semi-supervised techniques with automated seed initialization. Artan Y; Yetik IS IEEE Trans Inf Technol Biomed; 2012 Nov; 16(6):1313-23. PubMed ID: 22665512 [TBL] [Abstract][Full Text] [Related]
45. Re: Predictive value of MRI in the localization, staging, volume estimation, assessment of aggressiveness, and guidance of radiotherapy and biopsies in prostate cancer. Siegel C J Urol; 2012 Oct; 188(4):1183-4. PubMed ID: 22971368 [No Abstract] [Full Text] [Related]
46. Pictorial review. Diagnosis of recurrent prostate cancer and its mimics at multiparametric prostate MRI. Notley M; Yu J; Fulcher AS; Turner MA; Cockrell CH; Nguyen D Br J Radiol; 2015 Oct; 88(1054):20150362. PubMed ID: 26268143 [TBL] [Abstract][Full Text] [Related]
48. Role of 3.0 T multiparametric MRI in local staging in prostate cancer and clinical implications for radiation oncology. Couñago F; Recio M; Del Cerro E; Cerezo L; Díaz Gavela A; Marcos FJ; Murillo R; Rodriguez Luna JM; Thuissard IJ; Martin JL Clin Transl Oncol; 2014 Nov; 16(11):993-9. PubMed ID: 24865628 [TBL] [Abstract][Full Text] [Related]
49. What is still needed to make focal therapy an accepted segment of standard therapy? van den Bos W; Muller BG; Ehdaie B; Scardino P; de la Rosette JJ Curr Opin Urol; 2014 May; 24(3):247-55. PubMed ID: 24637317 [TBL] [Abstract][Full Text] [Related]
50. How are we going to train a generation of radiologists (and urologists) to read prostate MRI? Puech P; Randazzo M; Ouzzane A; Gaillard V; Rastinehad A; Lemaitre L; Villers A Curr Opin Urol; 2015 Nov; 25(6):522-35. PubMed ID: 26375060 [TBL] [Abstract][Full Text] [Related]
51. A urologists' guide to the multi-parametric magnetic resonance imaging (mpMRI)-galaxy. Kastner C BJU Int; 2015 Apr; 115(4):503-4. PubMed ID: 25808711 [No Abstract] [Full Text] [Related]
52. Doubling our precision of risk stratification in early prostate cancer: too good to be true? Emberton M BJU Int; 2016 Jan; 117(1):8-9. PubMed ID: 26676679 [No Abstract] [Full Text] [Related]
53. Cross-device automated prostate cancer localization with multiparametric MRI. Artan Y; Oto A; Yetik IS Annu Int Conf IEEE Eng Med Biol Soc; 2012; 2012():6247-50. PubMed ID: 23367357 [TBL] [Abstract][Full Text] [Related]
54. Oncologist criticises NICE for not recommending wider use of MRI in prostate cancer. Watts G BMJ; 2014 Jan; 348():g174. PubMed ID: 24412843 [No Abstract] [Full Text] [Related]
55. The use of hyperpolarised Woitek R; Gallagher FA Br J Cancer; 2021 Mar; 124(7):1187-1198. PubMed ID: 33504974 [TBL] [Abstract][Full Text] [Related]